**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 71-year-old man developed chylothorax and right pleural effusion during treatment with dasatinib for chronic myeloid leukaemia \[*not all duration of treatment to reaction onsets stated*\] [1](#Fn1){ref-type="fn"}.

The man, who had a history of chronic myeloid leukaemia, presented to the hospital due to shortness of breath. Approximately 20 years previously, he had undergone allogeneic sibling-matched stem cell transplantation. However, his condition relapsed. Four months prior to current presentation, he started receiving dasatinib daily \[*dose and route not stated*\]. At presentation, he had cough with bloody sputum, shortness of breath on exertion and low grade fever. Respiratory viral panel was positive for coronavirus. A large right pleural effusion with right lower and middle lobe compressive atelectasis were noted on a chest CT scan. Chylothorax was suspected secondary to dasatinib.

The man underwent thoracentesis. Pleural fluid was drained, which was cream in color with predominance of lymphocytes and triglyceride. Malignancy was ruled out via cytology. His treatment with dasatinib was discontinued. Eventually, his condition improved.

**Author comment:** *\"Dasatinib-related pleural effusions have been reported in 28-35% of patients; however, chylothorax is a rare complication\".*

Reporter country was not stated. Abstract presented at Chest Conference: CHEST 2019 Annual Meeting United States.
